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Abstract
Retinoblastoma is a rare eye tumor of childhood that arises in the retina. It is the most common
intraocular malignancy of infancy and childhood; with an incidence of 1/15,000–20,000 live births.
The two most frequent symptoms revealing retinoblastoma are leukocoria and strabismus. Iris
rubeosis, hypopyon, hyphema, buphthalmia, orbital cellulites and exophthalmia may also be
observed. Sixty per cent of retinoblastomas are unilateral and most of these forms are not
hereditary (median age at diagnosis two years). Retinoblastoma is bilateral in 40% of cases (median
age at diagnosis one year). All bilateral and multifocal unilateral forms are hereditary. Hereditary
retinoblastoma constitutes a cancer predisposition syndrome: a subject constitutionally carrying an
RB1 gene mutation has a greater than 90% risk of developing retinoblastoma but is also at increased
risk of developing other types of cancers. Diagnosis is made by fundoscopy. Ultrasound, magnetic
resonance imaging (MRI) and computed tomography (CT) scans may contribute to diagnosis.
Management of patients with retinoblastoma must take into account the various aspects of the
disease: the visual risk, the possibly hereditary nature of the disease, the life-threatening risk.
Enucleation is still often necessary in unilateral disease; the decision for adjuvant treatment is taken
according to the histological risk factors. Conservative treatment for at least one eye is possible in
most of the bilateral cases. It includes laser alone or combined with chemotherapy, cryotherapy
and brachytherapy. The indication for external beam radiotherapy should be restricted to large
ocular tumors and diffuse vitreous seeding because of the risk of late effects, including secondary
sarcoma. Vital prognosis, related to retinoblastoma alone, is now excellent in patients with
unilateral or bilateral forms of retinoblastoma. Long term follow-up and early counseling regarding
the risk of second primary tumors and transmission should be offered to retinoblastoma patients.
Disease name
Retinoblastoma.
Definition
Retinoblastoma is a rare eye tumor of childhood that
arises in the retina and represents the most common
intraocular malignancy of infancy and childhood [1]. It
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may occur at any age but most often it occurs in younger
children, usually before the age of two years.
Epidemiology
The incidence is 1 in 15,000–20,000 live births. In 60% of
cases, the disease is unilateral and the median age at diag-
nosis is two years. Of these cases, 15% are hereditary.
Retinoblastoma is bilateral in about 40% of cases with a
median age at diagnosis of one year. All bilateral and
multifocal unilateral forms are hereditary.
Clinical description
Leukocoria (white reflection in the pupil) and strabismus
are the most frequent clinical manifestations of retino-
blastoma (Figure 1). Leukocoria is initially inconstant,
visible only at certain angles and under certain light con-
ditions. This sign may be seen on flash photography. Stra-
bismus, when present, becomes rapidly constant,
reflecting impairment of the vision. These signs are still
all-too-often overlooked and justify an ophthalmological
consultation with ocular fundus examination. Some other
signs may be observed, including iris rubeosis, hypopyon,
hyphema, buphthalmia, orbital cellulitis, and exophthal-
mia. Some children with retinoblastoma may have no
symptoms. Screening in case of familial history or dys-
morphic syndrome with a 13q14 deletion [2] may lead to
diagnosis of retinoblastoma. Most affected children are
diagnosed before the age of five years.
Etiology
Retinoblastoma is the first disease for which a genetic eti-
ology of cancer has been described and the first tumor
suppressor gene identified. Knudson in 1971 developed
the hypothesis that retinoblastoma is a cancer caused by
two mutational events [3]. This led to the understanding
that there are two forms of retinoblastoma, germinal and
non germinal. Loss or mutations of both alleles of the
retinoblastoma gene RB1, localized to chromosome
13q1.4 [4], are required to develop the disease. In heredi-
tary cases (representing approximately 55% of the cases)
patients carry a germline inactivated RB1 allele present in
all cells in the body and somatic loss of the second allele
in retinal cells. Germinal RB1 mutations with a high pen-
etrance rate (> 90%) concern all patients with bilateral
retinoblastoma as well as 15% of patients with the unilat-
eral form. In non hereditary cases (45% of all patients)
both RB1 alleles are inactivated somatically in a single
developing retinal progenitor cell. In these cases, retino-
blastoma is always unilateral and unifocal.
The RB1 gene, composed of 27 exons, encodes for a 110
kD nuclear phospoprotein (pRB). pRB, a tumor suppres-
sor gene, is a regulator at the cell cycle check point
between G1 and entry into S phase. In the knock-out
mouse model of retinoblastoma, Zhang et al. demon-
strated that pRB is required for appropriate exit from the
cell cycle of retinal progenitor cells and for rod develop-
ment [5]. Numerous studies indicate that other molecular
events, in addition to the loss of pRB, are necessary for
tumorigenesis (chromosomal gain +1q, +6p; chromo-
somal loss -16, -16q, -17, -17p) [6,7].
A novel theory about the potential mechanism of retino-
blastoma tumor development was proposed in response
to the observation that spontaneous unilateral retinoblas-
toma may be more frequent in non industrialized coun-
tries. Orjuela et al., in a study evaluating the presence of
oncogenic human papilloma virus (HPV), concluded that
Leukocoria Figure 1
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pRB inactivation could be caused in part by the oncopro-
tein HPV E7 [8]. Environment (low folate intake during
pregnancy) was also postulated to play a role in the risk of
retinoblastoma occurrence because of the increased inci-
dence of unilateral retinoblastoma in developing coun-
tries [9].
Diagnostic methods
An examination of the ocular fundus under general
anesthesia leads to diagnosis. The lesion appears as a
white tumor with angiomatous dilatation of the vessels
(Figure 2).
Ocular ultrasound demonstrates a mass more echogenic
than the vitreous, with fine calcifications. Retinal detach-
ment may also be observed in exophytic forms (Figure 3).
Magnetic resonance imaging (MRI) is the imaging modal-
ity of choice to assess the local extension. The mass has a
signal equivalent to or a slightly more intense than that of
the vitreous on T1-weighted sequences, with a relatively
low-intensity signal on T2-weighted sequences (Figure 4).
Fine calcifications are not visible. MRI can depict exten-
sions to the optic nerve, anterior chamber and orbital fat.
MRI may be useful for distinguishing retinoblastoma
from pseudotumoral conditions such as Coats disease or
eye malformations and to diagnose rare cases of trilateral
retinoblastoma (third tumor in the pineal gland or para-
sellar region) (Figure 5) [10].
Computed tomography (CT) typically shows an intraocu-
lar mass with a higher density than the vitreous body, cal-
cified in 90% of cases and moderately enhanced after
iodine contrast agent injection.
Differential diagnosis
The rare, invasive, diffuse forms of retinoblastoma, usu-
ally not calcified, are very difficult to diagnose due to their
atypical and radiological features, mimicking an advanced
form of Coats disease and Toxocara Canis eye infection
MRI pattern of retinoblastoma with optic nerve involvement  (sagittal enhanced T1-weighted sequence) Figure 4
MRI pattern of retinoblastoma with optic nerve involvement 
(sagittal enhanced T1-weighted sequence).
Ocular fundus aspect of retinoblastoma Figure 2
Ocular fundus aspect of retinoblastoma.
Ultrasound of retinoblastoma Figure 3
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[10]. Coats disease corresponds to a unilateral retinal dis-
ease with telangiectasia and subretinal exudates. Persist-
ence of the primitive vitreous may also be mistaken for
retinoblastoma [11].
Genetic counseling
Genetic counseling should be proposed to every parent
having a child with retinoblastoma and to patients having
a familial history of retinoblastoma. During this consulta-
tion, the progress of management of retinoblastoma and
anticipated examination schedule for testing should be
presented to the family. An analysis of the child's personal
and familial history, and direct and indirect molecular
studies should be performed by the geneticist.
Young age at diagnosis, multifocal nature of the tumor,
presence of psychomotor retardation and a malformative
syndrome, and presence of a familial history of retino-
blastoma and retinoma suggest a genetic predisposition
for the disease. The risk of transmission is a function of
the familial history and the type of retinoblastoma. In case
of hereditary retinoblastoma, the risk of transmission is
50%. In case of unilateral, unifocal, non familial retino-
blastoma, the risk of transmission is 5%.
Genetic analysis in affected children may include the fol-
lowing molecular tests:
￿ Direct search for a constitutional mutation of the RB1 gene
performed on the constitutional DNA. The mutation detec-
tion rate is very high in hereditary forms [12]. No prefer-
ential mutation or "hot spot" has been identified in the
RB1 gene [13-16].
￿ Indirect demonstration of the allele carrying the mutation in
cases of familial history. This test consists of identifying
intragenic or RB1  flanking markers common to all
affected members of the family.
￿  Tumor loss of heterozygosity evaluation. This technique
requires tumor material and allows determination of
which allele is remaining and carrying the mutation.
During this consultation, patients should be informed of
the risks of transmission and of second primary tumor
development [17,18]. At present, there is no evidence that
a particular abnormality of the RB1 gene is associated with
a higher risk of second cancer.
Antenatal diagnosis
Antenal diagnosis may be proposed in case of hereditary
form with an identified RB1 mutation. Indirect detection
of the allele carrying the mutation may be used.
Several groups have started to investigate the use of preim-
plantation genetic diagnosis (PGD) for families who have
children with germinal retinoblastoma. Abramson et al.
recently reported the first live birth of a healthy newborn
to a couple in which the father had an history of germinal
retinoblastoma [19].
Management including treatment
Treatment of retinoblastoma is based on the bilateral or
unilateral characteristics of the retinoblastoma, on the
staging performed by the fundoscopy and the extension of
the disease.
Work-up for retinoblastoma
The fundus is examined under general anesthesia by indi-
rect ophthalmoscopy allowing visualization of the entire
retina, from the posterior pole to the most anterior zone.
It determines:
￿ the unilateral or bilateral nature of the lesions
￿ the number of tumors
￿ their situation in the retina (posterior pole, anterior ret-
ina)
￿ the tumor size (diameter, thickness)
￿ the subretinal fluid and tumor seeds
Aspect of trilateral retinoblastoma (MRI) Figure 5
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￿ the vitreous seeding: localized or diffuse
￿ the anatomical relations with the optic disc and macula
All these parameters should be taken into account for
grouping the retinoblastoma and for making therapeutic
decisions.
Two classifications are currently used for grouping
intraocular retinoblastoma: 1) the Reese Ellsworth classi-
fication, according to the chance of preserving the eye
using external beam radiotherapy (Table 1 and 2) the new
ABC classification, according to the chance of preserving
the eye using all modern therapeutic approaches (Table 2)
[20]. An international retinoblastoma classification
(Table 3) covering the whole spectrum of the disease
(from intraretinal to the presence of overt extra-ocular
extension) has been recently proposed [21]. In addition, a
proposal for a substaging (according to the histopatholog-
ical features of enucleated specimens) may further help to
differentiate patients with intraocular disease. The intraor-
bital staging is based on CT or MRI imaging, which must
be performed in almost all patients. Radiologically visible
extension to the retrolaminar optic nerve must be investi-
gated, especially in case of optic disc involvement, as it
determines the surgical approach for enucleation. Distant
staging looking for metastasis may also be performed
when enucleation is necessary and histopathological risk
factors have been identified (lumbar puncture, bone mar-
row aspiration) [22] (Table 4).
Management of localized form of retinoblastoma
Treatment approaches have changed over the past decade.
Many centers in recent years tried to increase the use of
chemotherapy and focal treatment methods, such as
transpupillary thermotherapy, photocoagulation and cry-
otherapy. These treatment methods were employed in an
effort to avoid the use of external beam radiation therapy.
Intraocular retinoblastoma continues to be managed by a
large number of treatment modalities including: enuclea-
tion, transpupillary thermotherapy, cryotherapy, laser
photocoagulation, brachytherapy, external beam radio-
therapy and chemotherapy (systemic and local delivery).
Management of extensive unilateral retinoblastoma
Enucleation is still often performed for extensive unilat-
eral retinoblastoma because of the elevated frequency of
extensive tumors (Group V, Reese Ellsworth classification
for retinoblastoma). The role of adjuvant treatment (that
aims to decrease the extraocular relapse) is debated; expe-
rienced pathologists advise avoiding this toxic treatment
in the majority of patients who would not benefit from
adjuvant chemotherapy [23-27]. Combinations of differ-
ent agents are used, such as carboplatin-etoposide and
vincristine-cyclophosphamide-doxorubicin. Orbital irra-
diation, external beam radiotherapy and interstitial radio-
therapy [28] is performed in the case of microscopically
incomplete resection. The management of extensive uni-
lateral retinoblastoma is summarized in the following
arborescence (Figure 6).
Management of bilateral retinoblastoma
In case of bilateral retinoblastoma, some conservative
approaches for treatment of at least one eye have been
developed (Figure 7). Their application depends on the
number of tumors, their situation in relation to the mac-
ula and the optic disc, the presence of partial or total reti-
nal detachment, the presence of invasion of the vitreous
and preretinal space, the age at diagnosis and the presence
of a familial history.
Table 1: The Reese Ellworth classification
Group I
a) solitary tumor, < 4 disc diameters in size, at or behind the equator
b) multiple tumor, none > 4 disc diameters in size, at or behind the equator
Group II
a) solitary tumor, 4–10 disc diameters in size, at or behind the equator
b) multiple tumor, 4–10 disc diameters in size, behind the equator
Group III
a) any lesion anterior to the equator
b) solitary tumor >10 disc diameters behind the equator
Group IV
a) multiple tumors, some >10 disk diameters
b) any lesion extending anteriorly to the ora serrata
Group V
a) massive tumors involving more than half the retina
b) vitreous seedingOrphanet Journal of Rare Diseases 2006, 1:31 http://www.OJRD.com/content/1/1/31
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The first conservative treatment used in the majority of
patients was external beam radiotherapy. Its use has
declined in many centers because numerous studies have
demonstrated serious adverse effects including cosmetic,
opthalmological, endocrine and neuro-cognitive seque-
lae, and, in particular, the increased risk of a second non-
ocular cancer in survivors of germinal retinoblastoma
[17,18]. Some of these adverse effects and the risk of
development of a second cancer may be more frequent if
external beam radiotherapy is delivered before one year of
age [29]. However, this age-limit for increased risk of a
second cancer is not constantly observed: in our own
series of secondary sarcomas within the radiation field, 8/
21 patients were irradiated after one year of age [17].
Table 3: International retinoblastoma classification
Stage 0: Patients treated conservatively (subject to presurgical ophthalmologic classifications)
Stage I: Eye enucleated, completely resected histologically
Stage II: Eye enucleated, microscopic residual tumor
Stage III: Regional extensiona
a) Overt orbital disease
b) Preauricular or cervical lymph node extension
Stage IV: Metastatic disease
a) Hematogenous metastasis:
1. single lesion
2. multiple lesions
b) CNS extension:
1. Prechiasmatic lesion
2. CNS mass
3. Leptomeningeal disease
Table 2: The ABC classification
Group A: small tumors away from foveola and disc
• Tumors <3 mm in greatest dimension confined to the retina and
• Located at least 3 mm from the foveola and 1.5 mm from the optic disc
Group B: all remaining tumors confined to the retina
• All other tumors confined to the retina and not in group A
• Subretinal fluid (without subretinal seeding) < 3 mm from the base of the tumor
Group C: local subretinal fluid or vitreous seeding
• Subretinal fluid alone >3 mm and < 6 mm from the tumor
• Vitreous or subretinal seeding < 3 mm from the tumor
Group D: diffuse subretinal fluid or seeding
• Subretinal fluid > 6 mm from the tumor
• Vitreous or subretinal seeding > 3 mm from the tumor
Group E: presence of any one or more of these poor prognosis features
• More than 2/3 of the globe filled with tumor
• Tumor in the anterior segment or anterior to the vitreous
• Tumor in or on the ciliary body
• Iris neovascularisation
• Neovascular glaucoma
• Opaque media from hemorrhage
• Tumor necrosis with aseptic orbital celullitis
• Phthisis bulbiOrphanet Journal of Rare Diseases 2006, 1:31 http://www.OJRD.com/content/1/1/31
Page 7 of 11
(page number not for citation purposes)
External beam radiotherapy remains an excellent way of
preserving eye vision in certain clinical situations (mas-
sive intraocular tumor, diffuse vitreous seeding).
Some other conservative techniques have been developed:
cryotherapy [30], brachytherapy [31], transpupillary ther-
mochemotherapy [32,33], systemic or local chemother-
apy with or without focal laser. Their indication depends
on the number, the localization (anterior retina or poste-
rior pole) and the size of the tumors.
Neoadjuvant chemotherapy may be administered in order
to make ocular tumors accessible to conservative manage-
ment, to allow conservative management other than
external beam radiation, to improve the visual prognosis
by promoting retinal reapplication and by decreasing or
Management of extensive unilateral retinoblastoma Figure 6
Management of extensive unilateral retinoblastoma.
Table 4: Staging of retinoblastoma
Ocular fundus under general anesthesia + → Any patient with retinoblastoma Schema, photographs, ultrasonography Reese grouping, new 
grouping
Brain and orbit CT scan or MRI + → Almost any patient with retinoblastoma (except neonatal screened patients with tumor 
respecting the head of optic nerve)
CSF cytology Bone marrow cytohistology + → When enucleation is necessary and shows histopathologic risk factors
Brain and spinal axis MRI Bone scan → Only in case of orbital, lymph node and/or distant metastatic diseases
CT – computed tomography
MRI – magnetic resonance imaging
CSF – cerebrospinal fluidOrphanet Journal of Rare Diseases 2006, 1:31 http://www.OJRD.com/content/1/1/31
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eliminating macular invasion, and to allow creation of
healthy retinal space between the tumor and the optic
disc. Cytotoxic agents used as a combination of two or
three drugs are carboplatin, etoposide and vincristine
[32,34-39]. The choice of agents, as well as the number
and frequency of cycles, may vary. In cases of paramacular
tumors, chemotherapy alone may be used [35].
After neoadjuvant chemotherapy, local treatment is used
in most of the cases. It includes laser treatment alone and
thermochemotherapy for tumors of the posterior pole,
and cryotherapy and brachytherapy for tumors of the
anterior pole. In case of vitreous seeding, external beam
radiotherapy, protontherapy and local administration of
carboplatin by subconjunctival injection are indicated
[40].
Follow-up for bilateral retinoblastoma
Fundoscopy, under general anesthesia until the age of
four or five years, should be performed every month dur-
ing the first year after the end of treatment. The interval
between examinations may then be gradually increased to
one examination every three months, even in case of uni-
lateral retinoblastoma (because of the risk of late bilateral
involvement) [41]. The objective is to detect new tumors
and ocular complications related to treatment. MRI and
ultrasound are necessary in case of vitreous hemorrhage
due to rupture of vitreoretinal adhesions or cataract, in
order to detect tumor progression before performing sur-
gery of these complications. Assessment of the orbital cav-
ity after enucleation should also be performed.
MRI could be useful to detect trilateral retinoblastoma.
Some argue that the infrequency of trilateral retinoblast-
oma does not warrant routine neuroimaging in patients in
Management of bilateral retinoblastoma Figure 7
Management of bilateral retinoblastoma.
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whom ocular disease is diagnosed [42]. However, Blach
and Col reported that patients with bilateral retinoblast-
oma have 6 to 8% risk of developing trilateral retinoblas-
toma until the age of six years and that early detection (by
MRI) in asymptomatic patients gives a better chance for a
cure [43]. Prognosis of patients with trilateral retinoblast-
oma remains poor, with most patients dying from pro-
gressive disease within 2 years of diagnosis. Meta-analysis
of trilateral retinoblastoma found that trilateral retino-
blastoma was detected earlier in patients undergoing rou-
tine serial imaging; in addition these patients survived
longer than those who did not undergo such imaging
[44]. Suggested screening programs for detection of trilat-
eral retinoblastoma widely vary [45]. Thus, interpretation
of a pineal tumor in a patient with bilateral retinoblast-
oma must be carefully done, taking into consideration the
recently described strong relationship between retinoblas-
toma and pineal cysts [46]. Pineal cysts may represent a
variant of trilateral retinoblastoma and warrant a less
aggressive therapeutic approach.
Ophthalmologic follow-up should include a complete
assessment of visual function (visual acuity, refraction dis-
orders) [47]. Pediatric follow-up is useful for detecting
sequelae of the treatment (second tumors, platin second-
ary ototoxicity) and for estimating the visual handicap.
Management of retinoblastomas with extraocular 
involvement
Extraocular involvement of retinoblastoma may concern
the soft tissues of the orbit, pretragal and cervical lymph
nodes, and metastases affecting bone, bone marrow and
the central nervous system (CNS). These forms, becoming
rare in industrialized countries, are still frequent in devel-
oping countries. Intensification of chemotherapy, based
on the use of high dose carboplatin, has greatly improved
the prognosis of the extraocular forms of retinoblastoma,
except in cases of CNS involvement [26,48,49].
Prognosis
Vital prognosis, related to retinoblastoma alone, is now
excellent in patients with unilateral or bilateral forms of
retinoblastoma, with a cure rate of 95% in industrialized
countries. The preservation of visual function depends on
ocular preservation, the initial tumor volume, the ana-
tomical relationships of the tumors with the macula and
the optic disk and the adverse effects of the treatments
(cataract, vitreous hemorrhage). Long term survival in the
hereditary form is threatened by the risk of occurrence of
second tumors [17,50]. A recently published study
reported a cumulative incidence for developing a new
cancer at 50 years after diagnosis of retinoblastoma of
36% for hereditary and 5.7% for non hereditary patients
[18]. Patients treated for hereditary retinoblastoma are at
an increased risk of developing non-ocular malignancies
due to a mutation in the second RB1 allele in different tis-
sues. External beam radiation, when administered before
the first year of life, and chemotherapy may also increase
the risk of development of second neoplasms [29,51]. The
most frequent tumors encountered are osteogenic sarco-
mas of the skull and long bones, soft tissue sarcomas,
cutaneous melanomas, brain tumors, and lung and breast
cancer. Although external beam radiotherapy is less
widely used than in the past, the risk of development of a
second tumor is still significant and patients should be
informed and carefully followed-up [52].
Unresolved questions
Despite the identification of the RB1 gene and the current
insight into the function of pRB, the understanding of the
sequence that leads to human retinoblastoma is still
incomplete. Recent development of new animal models
of retinoblastoma will increase the knowledge on tumor-
igenesis and provide an opportunity to develop treatment
strategies [5]. Although retinoblastoma has a good prog-
nosis in industrialized countries, mortality due to devel-
opment of a second tumor remains high. Development of
a non-mutagenic therapy (such as photodynamic ther-
apy) could be interesting, particularly in case of hereditary
retinoblastoma [53-55]. Gene therapy for treatment of
retinoblastoma is under evaluation [56].
In developing countries, retinoblastoma is unfortunately
accompanied by a high mortality rate due to a signifi-
cantly delayed diagnosis made at advanced stages of the
disease.
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